Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Klinische Wirksamkeit (39 Abbildungen)
Übersicht


Zum ersten Bild Abb. 6: Morgendliche Blutdrucksenkung - Angiotensin-I-Rezeptorblocker Abb. 7: Telmisartan - Losartan Abb. 8: Telmisartan - Losartan Aktuelles Bild - Abb. 9: Telmisartan - Losartan Abb. 10: Telmisartan - Losartan Abb. 11: Telmisartan - Losartan - Studienverlauf Abb. 12: Telmisartan - Losartan - Systolischer Minimaldruck Zum letzten Bild
Abbildung 9: Telmisartan - Losartan
The superiority of telmisartan over losartan is also evident when a flexible-dosing regimen is employed. This slide shows the results of an 8-week study in 331 patients with mild-to-moderate hypertension.1 Patients were started at the lower dose, with up-titration to the higher dose allowed if seated trough cuff DBP was ≥90 mmHg at Week 4. By Week 8, the reduction in SBP and DBP in the last 6 h of the dosing interval was greater in the telmisartan arm than in the losartan arm. 1. Data on file. Boehringer Ingelheim GmbH.
 
Telmisartan - Losartan
Vorheriges Bild Nächstes Bild   


Abbildung 9: Telmisartan - Losartan
The superiority of telmisartan over losartan is also evident when a flexible-dosing regimen is employed. This slide shows the results of an 8-week study in 331 patients with mild-to-moderate hypertension.1 Patients were started at the lower dose, with up-titration to the higher dose allowed if seated trough cuff DBP was ≥90 mmHg at Week 4. By Week 8, the reduction in SBP and DBP in the last 6 h of the dosing interval was greater in the telmisartan arm than in the losartan arm. 1. Data on file. Boehringer Ingelheim GmbH.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung